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The results of breast cancer screening projects such as the
HIP-trial in New York (Shapiro et al., 1982), the DOM-
project in Utrecht (Collette et al., 1984), the Nijmegen
screening project (Verbeek et al., 1984), the Swedish trial
(Tabar et al., 1985) and the screening programme in
Florence (Palli et al., 1986) show a considerable reduction of
breast cancer mortality. But even though it is no longer
disputed that early detection and early treatment lower the
mortality of breast cancer, some problems remain to be
solved. One of the problems inherent to screening is that a
number of women who have been identified by mammo-
graphy as suspect for having malignant lesions will turn out
to be false-positive cases at additional examinations (Peeters
et al., 1987).
A cohort study was conducted to find out whether a false
positive screening test result itself could be a risk factor for
developing breast cancer. Women were recruited from the
population-based screening project. This project started in
January 1975 with biennial mammography as the only
screening examination. The first screening round was
conducted in 1975/1976 among women born in the period
1910-1939 (n=23,000). In the subsequent screening rounds
women born before 1910 were invited too; in the fifth
screening round in 1983/84 the birth cohort 1940-1944 was
invited. All mammograms are read by the radiologist, who
decides if referral is necessary. Referral for clinical
examination was called for after the presence had been
established of direct signs suspect for malignancy such as,
e.g., a developing or progressive density (a mass), and/or
specific calcifications. Other reasons for referral were indirect
signs such as asymmetry of breast tissue or skin thickening,
nipple retraction or diffuse lymphoedema developed since the
previous screening examination. In 5 screening rounds a
total number of 801 women were referred to hospital to be
clinically examined after a single view mammography at the
screening centre. Those referrals with a diagnosis of breast
cancer within one year after referral were classified as
women with a true positive screening result. Breast cancer
was diagnosed in 302 of the referrals within 1 year after
referral. Nine women were not classified. They never passed
the general practitioner for various reasons: six of them were
of old age (78 or over); three of them refused clinical
examination. Of the remaining 490 referred women 28 were
lost to follow-up because they had moved outside the area or
had died within one year after referral. In this way 462
women were classified as having a false positive test result,
i.e., although suspect lesions were seen at the mammograph
screening examination, no breast cancer was diagnosed
within one year after referral. The women eligible for this
study of false-positive screening results were referred between
January 1975 through March 1984 during one of the 5
screening rounds. March 1, 1985 was set as the date line to
register whether and if so, when breast cancer was diagnosed
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during the intermediate follow-up period, starting 1 year
after referral. The follow-up period for each individual was
computed in person months (Kleinbaum et al., 1982). As a
reference group a sample was taken of all women who had
never been referred. Because the 462 women with a false-
positive test result were referred in different screening
rounds, the reference group was stratified accordingly on
screening round and age. Analogously to women with a false
positive screening test, all women who developed breast
cancer within one year after their screening examination
were not enrolled into the reference group. To increase
statistical efficiency a 1:4 sample was taken, resulting in a
reference group of 1,865 women with a true negative test
result. Breast cancers occurring in both groups were histo-
logically confirmed.
As was expected because of the design of the study, the
distribution of age and follow-up time were similar in both
groups. The mean age was 54.0 years for women with a false
positive test result, and 53.8 years for true negatives. The
mean follow-up time for women with a false positive test
result was 62.8 months, compared with 64.0 months for the
reference group. Sixteen breast cancer cases occurred among
the group with a false-positive result in a total follow-up
time of 28,811 months. The reference group had a total
follow-up time of 117,604 months, during which 24 breast
cancer cases were diagnosed. See Table I.
It can be concluded from Table I that the incidence rate
for women with a false-postive test result was 0.56 per 1,000
months, which is significantly higher (P=0.0006) than the
incidence rate of 0.20 per 1,000 months in the reference
group. Next, the distribution of age and follow-up time of
the breast cancer cases in both groups were compared.
Women who developed breast cancer after a previous false-
positive test result were older when compared with women
who developed breast cancer in the reference group (94%
were 50 years or older, compared to 79% in the reference
group). They also showed a shorter follow-up time. Sixty-
three per cent turned out to have breast cancer within 2
years after the previous false-positive test result, while only
37% developed breast cancer in the reference group. These
findings were not statistically significant. The histological
pattern of the carcinomas is presented in Table II.
Revision of all radiological, clinical, cytological and histo-
logical data of the cancer cases was performed in order to
clarify the observed higher incidence in the false-positive
group (see Table I). In one case additional mammography
did not confirm the original diagnosis and the patient had
been discharged. In 6 of the 16 cases the mammographically
detected lesion was not included in biopsy specimen. This
can be explained by the lack of routine specimen X-ray of
biopsies (Holland et al., 1985) in the early years of the
screening programme or by poor radiologic localisation due
to small diameter and/or deep situation of the tumour and/
or density of the breast. Some time lapsed before radio-
logical tests and clinical examination were carried out. In
three cases the suspect lesion was removed by biopsy, but
not recognised as malignant on histological examination.
Two of these lesions happened to be of a special type of
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Table I Occurrence of breast cancer in women with a false positive
screening test, and in women of the reference group
Women with false positive Reference
screening result group
Number of cancers 16 24
Follow-up time in months 28,811 117,604
Incidence per 1000 months 0.56 0.20
Value of the Z-statistic is 3.23; P=0.0006.
Table II Distribution of histological pattern of tumours diagnosed
in women with a false positive screening test and in women of the
reference group
Histological Cases in false Cases in the
pattern positive group reference group
Ductal carcinoma in situ 2 -
Ductal carcinoma invasive 7 18
Lobular carcinoma in situ I -
Lobular carcinoma invasive 1 3
Tubular carcinoma 5 3
Total 16 24
ductal carcinoma in situ, e.g. micropapillary intraductal
carcinoma. The third one, a minimal tubular carcinoma, was
not included in the paraffin block, but was present un-
recognised in the formalin jar. Twice a delay of more than
one year occurred, because of a delay in referral by the
general practitioner. The results of the revision show that in
12 of the 16 cases breast cancer was present at the time of
referral. Had all of these 12 women been worked up in the
proper manner, all of them would have been diagnosed and
dealt with in time considerably shorter than one year.
Analysis of the remaining 4 cases showed that the mammo-
graphic lesion which initially necessitated referral was not the
same as the cancer which developed later on. The occurrence
of just 4 breast cancer cases in women with a false-positive
screening test involving a total follow-up time of 28,503
months yields an incidence rate of 0.14 per 1,000 months,
which does not differ significantly (P=0.76) from the
incidence rate for women of the reference group.
The aim of this study was to find out whether a false-
positive screening result is a risk indicator for developing
breast cancer. In our analysis the study population consisted
of women with a history of a false-positive screening result:
although they were referred because of suspect mammo-
graphical signs, no malignancy was diagnosed within one
year after referral. Mammographical lesions known to be
associated with benign breast disease, such as cysts or
fibroadenoma, are no reason for referral in the screening
programme for early detection of breast cancer as long as
there are no complaints or mammographical signs suspect
for cancer! Nor is a false-positive referral identical to
histologically proven benign disease, Thirty per cent of the
462 women falsely referred never even had a biopsy. The
purpose of this study was not to arrive at any conclusions
about breast cancer risk in women with benign breast
diseases (Peterson & Williams, 1980; Moskowitz et al., 1980;
Webber & Boyd, 1986), but about the risk of breast cancer
in women with a false-positive screening result. This risk was
computed to be 2.7 times as high as that in a reference
group of women who have been screened, but never referred
because of an abnormality. After revision, the apparently
increased risk disappeared. To avoid the pitfalls inherent to
the diagnostic procedure of asymptomatic women referred
from the screening programme, regular meetings should be
held by the diagnostic team including the radiologist, the
surgeon and the pathologist. It is also mandatory to follow
carefully designed protocols in the diagnostic procedure. It
should be borne in mind, however, that when a new
screening programme is launched, a lack of experience in
reading and judging screen detected lesions will inevitably
manifest itself. Therefore radiologists, pathologists and
surgeons should be trained for the specific requirements of
diagnosis in a screening setting (Tabfar & Dean, 1987). After
revision the incidence rate in the false-positive group (0.14
per 1,000 months) turned out to be somewhat lower
compared with the reference group (0.20 per 1,000 months).
One possible explanation could be that some women of the
reference group were classified as not having cancer at the
screening examination, while they in fact already had cancer.
Indeed, revision of the mammograms showed that in one
patient breast cancer was present at the time of examination
and in two others the location of the breast cancer which
developed later on was not represented on the screening
mammogram. The follow-up time was on average 5 years for
both groups. This may be too short to find any increase in
risk. So far, however, no evidence has been found for any
increased risk for women who have had a- false-positive
screening test, if they are very carefully examined. Even for
women who had a follow-up time of more than 8 years
(20% of our study population), no increased risk was
observed either.
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